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Objective.The goal of this studywas to assess the concerns pregnantwomenhave about inﬂuenza vaccination
while breastfeeding and to determine if having these concerns represents a barrier to vaccination uptake.
Methods. The Vaccines and Medications in Pregnancy Surveillance System (VAMPSS) conducted a prospec-
tive cohort study in the US and Canada of inﬂuenza vaccine safety among pregnant women, oversampling vacci-
nated women. Data for the present paper are from an additional cross-sectional telephone survey completed
during the 2010–2011 and 2012–2013 inﬂuenza seasons.Results. We surveyed 431 pregnant women about their attitudes regarding inﬂuenza vaccination while
breastfeeding. Almost half of the participants identiﬁed one or two concerns and 4% reported three ormore con-
cerns. About one quarter reported that they would be unlikely to have an inﬂuenza vaccination while
breastfeeding. In the multivariate model, those reporting 1–2 concerns (OR = 0.16, 95% CI 0.09–0.28) and
those reported 3 or more concerns (OR = 0.07, 95% CI 0.02–0.22) had lower odds of being likely to vaccinate.
Conclusions. Pregnant women and postpartum women who are breastfeeding could beneﬁt from receiving
information and recommendations speciﬁc to vaccination from their healthcare providers, with a focus on
discussing known risks and beneﬁts to the baby's health.© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Breastfeeding women represent a high priority group for seasonal
inﬂuenza vaccination (CDC, 2010). Infants cannot get the vaccination,
but are especially vulnerable during their ﬁrst six months and have sig-
niﬁcantly higher rates of inﬂuenza-related hospitalization than older
children (Izurieta et al., 2000; Rasmussen et al., 2012; Yen et al.,
2012). Physical changes that occur during pregnancy put postpartum
women at high risk for severe illness and complications (Louie et al.,
2011; Rasmussen et al., 2012). While inﬂuenza vaccination is a priority
during pregnancy, (Callaghan et al., 2010; CDC, 2010; Creanga et al.,
2010) not all pregnant women get vaccinated, which may put them
and their infants at higher postpartum risk (Maertens et al., 2014). Preg-
nantwomen aremore likely to have an inﬂuenza vaccinationwhen they
feel more susceptible to inﬂuenza, perceive greater vaccine effective-
ness, are recommended to do so by a healthcare provider, anticipate
greater regret for not being vaccinated, and express fewer concerns
about potential adverse side effects to themselves and their baby
(CDC, 2011; Fisher et al., 2011; Fridman et al., 2011; Goldfarb et al.,
2011; Gorman et al., 2012; Henninger et al., 2013; Yudin et al., 2009).s).
. This is an open access article underFactors inﬂuencing decisions about vaccination while breastfeeding
are not known.
Breast milk offers a protective effect to infants, including for infant
mortality, gastrointestinal tract infection and respiratory tract infection,
and is recommended for at least the ﬁrst six months of life (Eidelman
et al., 2012). For women who receive an inﬂuenza vaccination during
pregnancy, there is some evidence of a protective effect from the trans-
fer ofmaternal antibodies either through the placenta or the breastmilk
(Schlaudecker et al., 2013; Zaman et al., 2008). However, the potential
impact of breastfeeding mother's inﬂuenza vaccination on her child's
health, including risks and beneﬁts, has not been determined. While
the CDC states that inﬂuenza vaccination (live or attenuated) is not con-
traindicated during breastfeeding (CDC, 2010), mothers have little on
which to base their decisions. Potential beneﬁts are suggested by re-
search involving women who receive an inﬂuenza vaccination during
pregnancy, but breastfeeding mothers may remain concerned about
the safety due to the lack of evidence and potential adverse infant
outcomes associated with some live attenuated vaccines given to
breastfeeding mothers (Alain et al., 2012; Lynch et al., 2012).
Public health efforts promoting inﬂuenza vaccination among preg-
nant women have resulted in greater uptake (CDC, 2011; Ding et al.,
2014). However, such efforts have not extended to postpartum,
breastfeeding mothers. It is unclear how many breastfeeding mothers
decline vaccination or for what reasons. The goal of this study was tothe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Respondent characteristics as correlates of likelihood of vaccination while breastfeeding
(N= 431).
Not likely
(n= 112)
n (%)
Likely
(n= 319)
n (%)
pa
Demographics
Age at EDD 0.073
Younger than 30 years 41 (36.6) 88 (27.6)
30 years or older 71 (63.4) 231 (72.4)
Socio-economic statusb 0.002
Low 11 (9.9) 22 (7.0)
Medium 21 (18.9) 25 (7.9)
High 79 (71.2) 269 (85.1)
Race/ethnicity 0.47
White (non-Hispanic) 85 (75.9) 258 (80.9)
Black 7 (6.3) 9 (2.8)
Hispanic/Latina 14 (12.5) 35 (11.0)
Asian/Pac Islander 4 (3.6) 13 (4.1)
Other/Unknown 2 (1.8) 4 (1.3)
EGA at time of survey 0.41
Fewer than 25 weeks' 55 (49.1) 171 (53.6)
25 weeks' or greater 57 (50.9) 148 (72.2)
Risk behaviors during current pregnancy
Any smoking 5 (4.5) 13 (4.1) 0.79
Any alcohol use 53 (47.3) 141 (44.2) 0.57
Reproductive history
Primigravida 45 (40.2) 140 (43.9) 0.50
Nulliparous 67 (59.8) 183 (57.4) 0.65
Previous miscarriage 27 (24.1) 75 (23.5) 0.90
Inﬂuenza vaccination history
Received inﬂuenza vaccine current season 57 (50.9) 286 (89.7) b0.001
Received inﬂuenza vaccine prior season 33 (29.5) 205 (64.3) b0.001
Note. EDD= estimated date of delivery. SD = standard deviation. EGA = estimated ges-
tational age. Participants from theUnited States and Canada interviewedduring the 2010–
11 and 2012–13 inﬂuenza seasons.
a Chi-square or Fisher's exact test.
b Socioeconomic status calculated using theHollingshead four factor index (Hollingshead,
1975) (N = 427).
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breastfeeding and to determine if having these concerns represent a
barrier to vaccination.
Methods
Vaccines and Medications in Pregnancy Surveillance System (VAMPSS)
The Vaccines and Medications in Pregnancy Surveillance System
(VAMPSS) inﬂuenza vaccine and medications study was initiated in
2009 to monitor and evaluate fetal and maternal risks of H1N1 vaccine,
seasonal inﬂuenza vaccine, and antiviral medications (Chambers et al.,
2013; Schatz et al., 2011). There are two parallel arms of VAMPSS, one
a prospective cohort study and the other a retrospective case–control
study.
Design of the cohort arm of VAMPSS
Participants in the prospective cohort arm of the VAMPSS study are
currently pregnant womenwho are self-referred, referred by their phy-
sicians, or referred by a network of 13 Teratogen Information Service
call centers, located in academic centers and health departments that
respond to calls from across the U.S. and Canada. These centers provide
free, evidence-based counseling and referral to about 70,000–100,000
callers each year about exposures during pregnancy and potential
risks for adverse birth outcomes. The cohort study planned to recruit a
sample of 1100 women, over-representing vaccinated women with ap-
proximately similar numbers vaccinated in each trimester. In the overall
sample, 82%were vaccinated during any trimester of pregnancy. The re-
mainder who were unvaccinated in any trimester of pregnancy served
as a comparison group. The study was designed to test speciﬁc hypoth-
eses related to adverse pregnancy outcomes in vaccinated compared to
unvaccinated pregnancies including risk of major birth defects, preterm
delivery, small for gestational age infants and post-natal growth deﬁ-
ciency in the ﬁrst year of life.
Additional survey
Participants in the VAMPSS prospective cohort studywere invited to
take an additional cross-sectional 15-minute telephone survey on their
beliefs about seasonal inﬂuenza vaccination during pregnancy and
breastfeeding. Not all cohort study participants were asked to complete
the additional survey due to telephone interviewer schedules and time
limitations for the participants. Surveys were conducted during two in-
ﬂuenza seasons (2010–11, 2012–13). Of 869 potentially eligiblewomen
enrolled in the cohort study during the survey time frames, 444women
(51%) completed the additional survey. The University of California, San
Diego Institutional Review Board approved the study.
Measurement
Likelihood of inﬂuenza vaccination while breastfeeding was
assessed using the following question: “Please imagine that you have
not had a seasonal ﬂu shot, have given birth, and are now breastfeeding
or pumping breast milk for your baby. How likely would you be to have
a ﬂu shot?” Those who responded “very likely” or “somewhat likely”
were deﬁned as “likely” to have an inﬂuenza vaccination while
breastfeeding. Those who responded “very unlikely” or “somewhat un-
likely”were deﬁned as “unlikely” to do so. Participants were then asked
the open-ended question, “What are your concerns about having a ﬂu
shotwhile breastfeeding or feeding your baby breastmilk?” Participants
either reported having “no concerns” or reported having concerns of
one or more type. We developed an initial list of categories describing
potential concerns based on a review of the literature and expanded it
based on responses. The ﬁnal list included 10 categories of concern.
We then summed the number of concerns, creating three groups:“None”, “1–2”, and “3 or more”. Demographics, reproductive history,
and risk behavior during pregnancy were obtained during VAMPSS in-
take interviews.
Analysis
In bivariate analyses, categorized continuous variables and com-
pared demographics, risk behaviors, reproductive history, inﬂuenza
vaccination, and number of concerns reported by likelihood of vaccina-
tion while breastfeeding, using chi-square tests and Fisher's exact test
where appropriate.We developed a logistic regressionmodel with like-
lihood of vaccination as the outcome variable. We used forward selec-
tion stepwise logistic regression, retaining only those variables with
p b 0.05. Prior year vaccination status, an indicator of annual vaccination
behavior, was considered for inclusion in the model. Finally, using chi-
square or Fisher's exact test, we compared the proportion in each likeli-
hood group (i.e., those not likely and those likely to have an inﬂuenza
vaccination while breastfeeding) who identiﬁed each area of concern.
We analyzed data in SAS Version 9.4 (SAS Institute, Inc., Cary, North
Carolina) using two-tailed tests (critical alpha b 0.05).
Results
Participant characteristics
This study includes 431 pregnant women (average 25 week
gestation) who provided information about likelihood of inﬂuenza
vaccination while breastfeeding. Most participants were white (non-
Hispanic) (80%), of high socioeconomic status (81%), nulliparous
Table 2
Logistic regression model of variables related to likelihood of inﬂuenza vaccination while
breastfeeding (N= 427).
Adjusted OR (95% CI)
Variable
SESa
High Ref.
Medium 0.46 (0.22–0.95)
Low 0.75 (0.31–1.82)
Number of concerns reported
None (ref) Ref.
1–2 0.16 (0.09–0.28)
3 or more 0.07 (0.02–0.22)
Prior year inﬂuenza vaccination 3.38 (2.01–5.69)
Note: Model adjusted for all variables shown in the table. Participants from the United
States and Canada interviewed during the 2010–11 and 2012–13 inﬂuenza seasons.
a Socioeconomic status calculated using theHollingshead four factor index (Hollingshead,
1975).
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and prior (55%) inﬂuenza seasons (Table 1). Compared to other partic-
ipants in the VAMPSS cohort study, thosewho completed the additional
surveyweremore likely to bewhite (non-Hispanic), nulliparous, and to
report having a high socioeconomic status (all with p b 0.05). There
were no differences across other demographic, risk behavior, or repro-
ductive history characteristics presented in Table 1. Differences in fac-
tors assessed only at the time of the additional survey, including
inﬂuenza vaccination status, prior year vaccination, and gestational
age at the time of the survey, cannot be determined.
Likelihood of inﬂuenza vaccination while breastfeeding
When asked to imagine that they were now breastfeeding, 112
(26%) reported that they would be unlikely and 319 (74%) reported
that they would be likely to be vaccinated. Those who were likely to
be vaccinated had higher socioeconomic status (p b 0.01), and more
likely to have received an inﬂuenza vaccine in both the current and
prior seasons (p b 0.001) (Table 1).
In the logistic regressionmodel, thosewhohad an inﬂuenza vaccina-
tion in the prior ﬂu season (OR = 3.38, 95% CI 2.01–5.69) had greater
odds of being likely to vaccinate. Those reportingmedium, as compared
to high socioeconomic status (OR = 0.46, 95% CI 0.22–0.95) had lower
odds of vaccination, as did those reporting one to two concerns
(OR = 0.16, 95% CI 0.09–0.28) and those reporting three or more con-
cerns (OR = 0.07, 95% CI 0.02–0.22) (Table 2).
Concerns about vaccination while breastfeeding
About half of participants (n = 218, 51%) reported having no con-
cerns, 196 (45%) reported one or two concerns, and 16 (4%) reportedTable 3
Concerns identiﬁed by those not likely and likely to have an inﬂuenza vaccination (N= 428).
Type of concern reported
No concerns
Safety of the vaccine or unknown risks
Mercury (or thimerosol) or other ingredients in the vaccine
Might harm my baby's physical health (including fever, illness, ﬂu symptoms)
Might cause developmental problems in my baby (including learning disabilities, autism
Might harm my health
In general, I am opposed to vaccination
I need more information about safety and recommendations (N = 427)
Worried about vaccine passing through breast milk and potential harm
Not necessary or beneﬁcial
Other concerns
Note: Includes participants reporting on both variables. Participants from the United States and
a Chi-square or Fisher's exact test.having three or more concerns about inﬂuenza vaccination while
breastfeeding. Themost common concerns reportedwere: vaccine safe-
ty and unknown risks of vaccination while breastfeeding (15%), poten-
tial harm to baby's physical health, such as fever or illness (14%), and
worry about potential harm to the baby because of the vaccine passing
through breast milk (12%). The proportion who identiﬁed each concern
was signiﬁcantly different across the likelihood groups, with the excep-
tion of those identifying concerns about developmental problems, infor-
mation needs about safety, and potential harm from the vaccine passing
through breastmilk, where differences between groupswere not signif-
icant (Table 3).
Discussion
Even in this high uptake study cohort, where 80% had received an in-
ﬂuenza vaccination during pregnancy, half of women expressed at
least one concern about inﬂuenza vaccination while breastfeeding.
These concerns represent barriers to vaccination, as thosewith a greater
number of concerns reported that they would be less likely to be vacci-
nated while breastfeeding. Our ﬁndings indicate that pregnant women,
particularly those who do not regularly receive inﬂuenza vaccinations
and those with lower socioeconomic status, need more information
about safety and recommendations regarding vaccination while
breastfeeding.
Healthcare providers play an important role in educating and
reminding pregnant women about inﬂuenza vaccination recommenda-
tions and safety (Ahluwalia et al., 2010; Ding et al., 2014; Goldfarb et al.,
2011; Gorman et al., 2012; Lynch et al., 2012). In this study, women
expressed the greatest number of concerns about unknown safety and
potential risks to the baby's health. Prenatal and postpartum visits are
ideal times for providers to address these concerns. However, given
the current limitations in evidence on beneﬁts and risks, breastfeeding
mothers may remain concerned about safety and could be less likely
to have a vaccination.While inﬂuenza vaccination during breastfeeding
is recommended, further research on child health outcomes may pro-
vide greater reassurance for those who remain concerned. The larger
cohort study fromwhich the present study sample was drawn provides
new evidence regarding the safety of vaccination during pregnancy
(Chambers et al., 2013; Schatz et al., 2011). The study design would
allow for data to be collected on the safety of vaccination for infants of
mothers who have an inﬂuenza vaccination while breastfeeding.
This study is the ﬁrst to speciﬁcally evaluate pregnant women's
anticipated concerns about having an inﬂuenza vaccination while
breastfeeding, and how these concerns relate to their intentions regard-
ing vaccination during that time. However, it does have several limita-
tions. First, this cross-sectional survey is not sufﬁcient to assess
whether intentions lead to future behavior, as it does not include a
follow-up assessment of vaccination behavior while breastfeeding.
This preliminary work needs to be conﬁrmed with evaluation of then (%) Not likely (n = 112) Likely (n = 316) pa
224 (50.7) 20 (17.9) 196 (62.0) b0.001
66 (15.4) 35 (31.3) 31 (9.8) b0.001
28 (6.5) 14 (12.5) 14 (4.4) 0.003
60 (14.0) 25 (22.3) 35 (11.1) 0.003
, ADD, delays) 25 (5.8) 8 (7.1) 17 (5.4) 0.49
13 (3.0) 11 (9.8) 2 (0.6) b0.001
13 (3.0) 10 (8.9) 3 (0.9) b0.001
32 (7.5) 10 (9.0) 22 (7.0) 0.48
50 (11.7) 18 (16.1) 32 (10.1) 0.092
9 (2.1) 7 (6.3) 2 (0.6) 0.002
11 (2.6) 9 (8.0) 2 (0.6) b0.001
Canada interviewed during the 2010–11 and 2012–13 inﬂuenza seasons.
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currently breastfeeding women. Study participants represent a conve-
nience sample drawn from a larger study of inﬂuenza vaccination dur-
ing pregnancy, so participants are not representative of the general
population of pregnant women and we cannot determine if this sample
is representative of the VAMPSS cohort across all characteristics. Be-
cause not all potential participants were asked to complete a survey,
we are also unable to determine if participant characteristicswere relat-
ed to study participation. Because a higher proportion of participants
(80%) than in the United States (52%) had an inﬂuenza vaccination dur-
ing pregnancy (Ding et al., 2014), this study may underrepresent the
concerns and potential impact on vaccination uptake. Finally, we did
not ask about the intensity of each concern, so a numerical count may
not represent the magnitude of concern equally across participants.
Conclusion
The results of this study indicate a need to provide additional infor-
mation about the recommendations for inﬂuenza vaccination while
breastfeeding, with a focus on the safety and risks for the baby. Addi-
tional research is needed to clearly identify both the beneﬁts and risks
of inﬂuenza vaccination choices for breastfeeding women and their
babies so that women can make informed decisions. Prenatal and post-
partum visits provide ideal education opportunities. This is particularly
critical during inﬂuenza season and for mothers with infants who are
too young to have an inﬂuenza vaccination, and could have signiﬁcant
public health beneﬁts.
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